Trial Profile
First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs MSB 2311 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MabSpace Biosciences
- 26 Feb 2021 Status changed from recruiting to completed.
- 13 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 05 Sep 2018 According to a MabSpace Biosciences media release, this study is planned to further explore efficacy in tumor-type specific or biomarker-enriched expansion cohorts.